Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Fineline Cube Dec 22, 2025
Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Fineline Cube Dec 22, 2025
Company Drug

Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jun 17, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...

Company Deals

BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development

Fineline Cube Jun 17, 2025

Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD...

Company Deals

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology

Fineline Cube Jun 17, 2025

US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...

Company Deals

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC

Fineline Cube Jun 17, 2025

China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...

Company Drug

AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial

Fineline Cube Jun 17, 2025

US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...

Company Legal / IP

Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute

Fineline Cube Jun 17, 2025

China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...

Company Drug

Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease

Fineline Cube Jun 17, 2025

Switzerland-based Roche (SWX: ROG, OTCMKTS: RHHBY) announced its decision to advance prasinezumab, an anti-α-synuclein antibody...

Company Deals

Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors

Fineline Cube Jun 17, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...

Company

AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June

Fineline Cube Jun 17, 2025

Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...

Company Deals

Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion

Fineline Cube Jun 17, 2025

US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...

Company Drug

Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray

Fineline Cube Jun 17, 2025

China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...

Company Drug

Minova Pharmaceuticals Launches Rongzhi, China’s First Injectable Adipocytolytic Drug

Fineline Cube Jun 17, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from...

Legal / IP

RemeGen Secures 1,827-Day Patent Extension for Telitacicept in China

Fineline Cube Jun 17, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced that the China National Intellectual Property Administration has...

Company Drug

Fujian Cosunter Gains Ethics Approval for Phase III Study of Neracorvir in CHB Patients

Fineline Cube Jun 17, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd. (SHE: 300436) announced that it has received ethical approval...

Company Drug

CDE Accepts NDA for Ark Bio’s Azstarys, a Priority-Reviewed ADHD Treatment

Fineline Cube Jun 17, 2025

China’s Center for Drug Evaluation (CDE) has officially accepted the New Drug Application (NDA) for...

Company Drug

Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918

Fineline Cube Jun 17, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...

Company Deals

Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts

Fineline Cube Jun 17, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the exercise of unilateral termination rights under its...

Company Drug

Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment

Fineline Cube Jun 17, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...

Policy / Regulatory

China’s NHC Unveils 2025 Healthcare Reforms to Tackle Procurement and Service Irregularities

Fineline Cube Jun 16, 2025

China’s National Health Commission (NHC) has released the 2025 Key Tasks for Rectifying Improper Practices...

Company Deals Medical Device

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence

Fineline Cube Jun 16, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) is reported by the Financial...

Posts pagination

1 … 77 78 79 … 600

Recent updates

  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
  • Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Company Drug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.